Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Maternal immunization: US FDA regulatory considerations.

Marion F Gruber1

  • 1Center for Biologics Evaluation and Research (CBER), US FDA, Woodmont Office Complex 1 Rockville Pike, Rockville, MD 20852, USA. gruber@cber.fda.gov

Vaccine
|July 10, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Report of a one-day convening on regulatory science, practices, and innovative approaches to facilitate approval of novel combination vaccines.

Vaccine·2026
Same author

Realising the potential of correlates of protection for vaccine development, licensure and use: short summary.

NPJ vaccines·2024
Same author

Enabling the evaluation of COVID-19 vaccines with correlates of protection.

Biologicals : journal of the International Association of Biological Standardization·2023
Same author

Approaches to demonstrating the effectiveness of filovirus vaccines: Lessons from Ebola and COVID-19.

Frontiers in immunology·2023
Same author

Current status of monkeypox vaccines.

NPJ vaccines·2022
Same author

Making more COVID-19 vaccines available to address global needs: Considerations and a framework for their evaluation.

Vaccine·2022
Same journal

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.

Vaccine·2026
Same journal

Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial.

Vaccine·2026
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
Same journal

Vaccine strategies and development before and during the 1968 H3N2 influenza pandemic.

Vaccine·2026
Same journal

Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024.

Vaccine·2026
See all related articles

Maternal immunization offers significant health benefits but faces challenges. Reviewing regulatory, preclinical, and clinical aspects is crucial for safe vaccine development in pregnant women.

Area of Science:

  • Immunology
  • Vaccinology
  • Maternal-Fetal Medicine

Background:

  • Vaccination during pregnancy is a key strategy for maternal and infant health.
  • Current vaccine development often excludes pregnant women, limiting safety data.
  • Increasing novel vaccine development raises concerns about unintentional fetal exposure.

Purpose of the Study:

  • To review regulatory, preclinical, and clinical considerations for vaccines intended for pregnant women.
  • To address the gap in safety data for vaccines used during pregnancy.
  • To inform the development of safe and effective maternal immunization programs.

Main Methods:

  • Review of existing regulatory guidelines for vaccine development.
  • Analysis of preclinical (animal model) developmental toxicity studies.

Related Experiment Videos

  • Examination of clinical trial data and safety monitoring in pregnant populations.

    • Main Results:

    • Most licensed vaccines are not indicated for pregnancy, despite benefits.
    • Safety conclusions often rely on animal data due to exclusion of pregnant women from trials.
    • There's a need for robust data collection on vaccine safety in pregnant women prior to licensure.

    Conclusions:

    • Vaccine development programs for pregnant women require careful consideration of regulatory, preclinical, and clinical factors.
    • Enhanced data collection and specific trials are needed to ensure vaccine safety during pregnancy.
    • Maternal immunization strategies necessitate a thorough risk-benefit assessment for both mother and infant.